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Abstract
Background: Newborn screening for mucopolysaccharidosis type I (MPS I) shows promise to improve outcomes
by facilitating early diagnosis and treatment. However, diagnostic tests for MPS I are of limited value in predicting
whether a child will develop severe central nervous system disease associated with Hurler syndrome, or minimal
or no central nervous system involvement associated with the attenuated phenotypes (Hurler–Scheie and Scheie
syndromes). Given that the optimal treatment differs between Hurler syndrome and the attenuated MPS I phenotypes,
the absence of a reliable prognostic biomarker complicates clinical decision making for infants diagnosed through
newborn screening. Information about the natural history of Hurler syndrome may aid in the management of affected
infants, contribute to treatment decisions, and facilitate evaluation of treatment effectiveness and prognosis. Thus, the
aim of this study was to characterize the progression and timing of symptom onset in infants with Hurler syndrome.
Results: Clinical data from 55 patients evaluated at a single center were retrospectively reviewed. Information about
each child’s medical history was obtained following a standardized protocol including a thorough parent interview
and the review of previous medical records. All patients underwent systematic physical and neurodevelopmental
evaluations by a multidisciplinary team. Nearly all patients (98%) showed signs of disease during the first 6 months of
life. Common early disease manifestations included failed newborn hearing screen, respiratory symptoms, difficulty
latching, and otitis media. Other symptoms such as kyphosis, corneal clouding, cardiac disease, joint restrictions, and
enlarged head circumference typically appeared slightly later (median age, 8–10 months). During the first 12 months,
gross motor development was the most severely affected area of functioning, and a significant number of patients also
experienced language delays. Cognition was typically preserved during this period.
Conclusions: In this large cohort of patients with Hurler syndrome, the vast majority showed signs and
symptoms of disease during the first months of life. More research is needed to determine the extent to
which early clinical manifestations of MPS I can predict phenotype and treatment outcomes.
Keywords: Mucopolysaccharidosis type I, MPS I, Hurler syndrome, lysosomal storage disorders, Newborn
screening, Natural history
Background
Mucopolysaccharidosis type I (MPS I, OMIM 252800) is
a rare lysosomal storage disorder caused by the defi-
ciency or complete absence of enzyme α-L-iduronidase
activity. Inadequate activity of this enzyme leads to the
accumulation of glycosaminoglycans throughout the
body, resulting in progressive multisystem deterioration.
Although MPS I is associated with a continuum of dis-
ease presentations, it has traditionally been divided into
three clinical phenotypes. Hurler syndrome, the most se-
vere form, typically manifests during the first year of life.
Affected children rapidly develop significant cognitive
impairment and somatic disease in multiple organ sys-
tems, leading to death within the first decade in the ab-
sence of treatment. The attenuated forms of MPS I,
known as Hurler–Scheie syndrome and Scheie syn-
drome, are characterized by later onset of symptoms,
longer life expectancy, and mild or no central nervous
system (CNS) involvement. Symptoms found across the
entire MPS I spectrum include corneal clouding, orga-
nomegaly, cardiac valve abnormalities, joint contrac-
tures, and dysostosis multiplex [1].
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Treatment for MPS I is based on clinical presentation.
Intravenous enzyme replacement therapy (ERT) is the
first-line treatment for individuals with the attenuated
forms of this disorder [2]. In these patients ERT has
been shown to improve quality of life and ameliorate
hepatomegaly, apnea, joint restrictions, and other som-
atic symptoms [3–5]. However, because the recombinant
enzyme cannot cross the blood–brain barrier, ERT alone
is generally not sufficient to manage the CNS manifesta-
tions associated with Hurler syndrome. For these pa-
tients, hematopoietic stem cell transplantation (HSCT)
is the mainstay of treatment, although ERT may be
added as an adjunct therapy [2]. Poe et al. (2014) found
that patients with Hurler syndrome who underwent
HSCT prior to 9 months of age showed relatively nor-
mal trajectories of cognitive development, whereas those
who were transplanted later experienced long-term defi-
cits [6]. These findings suggest that HSCT may be able
to halt the progression of cognitive decline but is less ef-
fective at reversing pre-existing neurological damage.
Thus, early treatment of affected individuals is crucial.
Historically, most patients with MPS I were diagnosed
only after the appearance of characteristic disease mani-
festations. However, pilot newborn screening (NBS) pro-
grams for this disorder have recently been implemented
in a number of locations, including Taiwan and Italy [7–
9]. Moreover, in February 2016 the U.S. Secretary of
Health and Human Services approved MPS I for
addition to the Recommended Uniform Screening Panel.
This development is likely to result in increased imple-
mentation of newborn screening for this disorder in the
coming years.
Early diagnosis of patients with MPS I shows promise
to improve outcomes. Nonetheless, the implementation
of routine newborn screening for this disorder will likely
pose a number of challenges for clinicians. To select the
most appropriate disease-modifying therapy (HSCT and/
or ERT) for each patient, clinicians will need to deter-
mine which infants are most likely to develop the severe
CNS involvement associated with Hurler syndrome.
However, the limited prognostic value of genetic and
biochemical tests complicates phenotype prediction at
the time of diagnosis for many patients [10–12]. In the
absence of a biomarker that can reliably predict disease
course, patients diagnosed with MPS I through newborn
screening must be monitored closely during the first
months of life.
Although only a subset of MPS I patients develop the
most severe phenotype, information about the natural
history of Hurler syndrome is relevant to the clinical
management of all newborns with MPS I. Knowledge of
the early natural history of Hurler syndrome may help to
limit delays between symptom onset and initiation of ap-
propriate supportive treatments, and enable clinicians to
proactively monitor all newborns with MPS I for com-
mon early disease manifestations. Characterization of
the earliest manifestations of Hurler syndrome may also
contribute to the identification of prognostic clinical
markers. These markers, in combination with other test
results, may help clinicians determine which infants are
the best candidates for HSCT and which should be
treated with less aggressive therapies such as ERT. More
data on the progression of early signs and symptoms of
Hurler syndrome are needed to serve as a comparator
for the evaluation of treatment effectiveness and to as-
sess the true clinical benefit of NBS once it is imple-
mented. However, because of the rarity of Hurler
syndrome, there is a paucity of research about its natural
history [1, 12–14]. Thus, the aim of this study was to
characterize the onset and progression of neurological
and somatic disease in a large cohort of patients with
Hurler syndrome who underwent standardized multidis-
ciplinary evaluations at a single center.
Methods
Inclusion and exclusion criteria
Clinical data were retrospectively reviewed from all
patients with a confirmed diagnosis of Hurler syn-
drome that were seen at the Program for the Study
of Neurodevelopment in Rare Disorders between 2000
and 2013 (n = 55). Diagnosis was based on deficiency
or complete absence of enzyme α-L-iduronidase activ-
ity, increased glycosaminoglycans in urine, and muta-
tion analysis predictive of phenotype, Hurler
phenotype or family history of Hurler syndrome. Only
data collected before treatment with HSCT were in-
cluded in the analysis.
Data acquisition
Disease onset and clinical course were characterized by
reviewing available outside medical records, parental re-
sponses to a detailed questionnaire, and clinical data col-
lected at the time of evaluation at our specialized
program. The parental questionnaire covered the child’s
prenatal and neonatal history, acquisition of develop-
mental milestones, behaviors, initial signs of disease, and
prior diagnoses, surgeries, and hospitalizations. When
available, the results of cardiac evaluations, brain and
cervical spine magnetic resonance imaging (MRI) scans,
and audiological assessments were also reviewed.
At each clinic visit, the patients underwent compre-
hensive physical and neurodevelopmental evaluations
performed over the course of 4–6 h by a team of
specialists including neurodevelopmental pediatricians,
speech-language pathologists, physical and occupa-
tional therapists, psychologists, and audiologists. Stan-
dardized, validated tests that are optimal for use in children
with lysosomal storage disorders were administered to assess
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function across several developmental domains (i.e., cogni-
tion, adaptive behavior, expressive and receptive language,
and gross and fine motor skills) [15]. Tests were selected on
the basis of each child’s estimated developmental age. To
minimize error, a pre-determined protocol that specified the
order of testing was followed. Results were reported as de-
velopmental age-equivalents to enable determination of the
increase or decrease of skills over time.
Statistical analysis
This is a retrospective and descriptive analysis of signs
and symptoms of Hurler syndrome. For some data (de-
velopmental and growth) a cross sectional and longitu-
dinal analysis was performed. Graphs were generated for
each developmental domain by plotting the age-
equivalent score (y-axis) against the patient’s actual age
at the time of testing (x-axis). The developmental graphs
also show a group mean curve, which was estimated
using a linear polynomial model or a non-linear mono-
molecular model. The monomolecular model seemed
more appropriate as it estimates three parameters: a
starting place (fixed at 0), plateau, and rate at which the
outcome reaches the plateau.
Results
Patient characteristics
Of the 55 patients with Hurler syndrome evaluated be-
tween 2000 and 2013, there were 23 boys (41.8%) and 32
girls (58.2%). Forty-four were evaluated once (n = 37) or
twice (n = 7) at our clinic prior to transplantation. A med-
ical record review was used to gather pre-transplantation
information for the 11 patients who were not evaluated in
our clinic prior to transplantation. One patient received
bone marrow transplantation from a related donor, and 43
received umbilical cord blood transplantation. Five pa-
tients also received ERT prior to transplantation. The
outcomes for a subset of these transplant patients have
been reported previously [16, 17]. Only one patient has
died due to natural progression of disease (age, 8.9 years).
Genotypic data available for a subset of this cohort have
been reported previously [16].
Information about medical history, including the tim-
ing of symptom onset (Fig. 1), was available for all 55 pa-
tients. However, physical examination findings were
available only for the 44 patients who had not under-
gone transplantation at the time of the initial evaluation
at this specialized program (Table 1). Growth data for
this cohort, including longitudinal measures of height,
weight, and head circumference, are shown in Fig. 2.
Initial presentation and diagnosis
Data from the prenatal period (available for 41/55 pa-
tients) were unremarkable in most cases. Eight of the 55
patients (14.5%) were born before 37 weeks of gestation,
and 24 (43.6%) were delivered via cesarean section.
Seven patients (12.7%) were noted to have orthopedic
abnormalities at birth including kyphosis (n = 4), talipes
equinovarus (n = 2), sacral dimple (n = 1), pectus carina-
tum (n = 1), and pectus excavatum (n = 1). Other con-
genital anomalies included hernias (n = 5), cardiac
defects (n = 3), and hypospadia (n = 2). Fifteen infants
(27.3%; 3 premature, 12 full-term) had hyperbilirubine-
mia during the neonatal period.
Most patients developed signs of disease during the
first months of life. The proportion of infants with at
least one of the following symptoms was 83.6% (n = 46)
by 1 month and 98.2% (n = 54) by 6 months: respiratory
difficulties, otitis media, hearing loss, corneal clouding,
hernias, organomegaly, hypotonia, feeding difficulties,
joint restrictions, enlarged head circumference, cardiac
disease, and kyphosis. Nonetheless, diagnostic delays
were common, and the patients in this cohort were not
Fig. 1 Median age of symptom onset with minimum to 9th decile range
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diagnosed with MPS I until a median of 9.3 months. The
most common symptoms that prompted the workup
leading to diagnosis were kyphosis (n = 19; 34.5%), de-
layed acquisition of motor or language milestones (n =
17; 30.9%), enlarged head circumference (n = 15; 27.3%),
corneal clouding (n = 10; 18.2%), and dysmorphic facial
features (n = 9; 16.4%).
Sensory functioning
Audiological
Hearing loss and otological disease were among the
earliest disease manifestations in this cohort. Fifteen of
the 33 patients with available results (45.5%) failed their
hearing screen at birth. Audiological evaluations, which
most commonly included behavioral audiometry (n = 23)
and/or auditory brainstem response testing (n = 19),
were subsequently performed in 42 patients. Hearing
loss was evident in 32 patients (76.2%), whereas 5 pa-
tients (11.9%) had normal hearing, and results were in-
conclusive for the remaining 5 patients. Of the 20
patients with available information about type of hearing
loss, 11 (55.0%) had predominantly sensorineural defi-
cits, and the other patients had predominantly conduct-
ive (n = 7; 35.0%) or mixed (n = 2; 10.0%) hearing loss.
Median age at the first failed hearing examination was
7.6 months. Symptoms of middle ear pathology were
present in the vast majority of patients. Forty-nine pa-
tients (89.1%) had a history of chronic middle ear effu-
sion and/or acute otitis media, which began at a median
of 6.5 months. These symptoms led to tympanostomy
tube insertion for 43 patients (78.2%) at a median age of
10.9 months.
Ophthalmologic
Corneal clouding was the most frequent ophthalmo-
logical finding (n = 36; 81.8%) and was present in all pa-
tients older than 15 months at the time of evaluation.
Corneal clouding was diagnosed at a median age of
10.1 months and was frequently preceded by a history of
photophobia. Pupillary responses were normal in all pa-
tients who were evaluated. Four patients had strabismus.
Feeding and oral-motor manifestations
Feeding difficulties affected 39 patients (70.9%) in this
cohort. Twelve patients (21.8%) had problems with
latching on to the breast or sucking during the first
month of life, and 17 (30.9%) developed symptoms of
gastroesophageal reflux. Swallowing issues were present
to varying degrees in 25 patients (45.5%) and com-
monly manifested as episodes of gagging or choking
on food (n = 19) and/or aspirating or coughing with
liquids (n = 8). Seven children (12.7%) were also noted
to have strong aversions to textured foods. Physical
characteristics that may have contributed to feeding
difficulties included macroglossia (n = 13; 29.5%), and
palate abnormalities (n = 9; 20.5%). Ten patients
(22.7%) had gingival hypertrophy. A number of pa-
tients also had problems with bowel movements such
as diarrhea (n = 10; 18.2%) and/or constipation (n = 7;
12.7%).
Somatic manifestations
Respiratory
Respiratory difficulties typically began soon after birth.
Fourteen infants (25.5%; 6 premature, 8 full-term) re-
quired respiratory support during the neonatal period.
An additional 18 patients (32.7%) developed other re-
spiratory symptoms during the first month of life, in-
cluding signs of upper airway obstruction (n = 16) and
infections (n = 2).
Even among patients with an unremarkable neonatal
course, the vast majority ultimately developed respira-
tory symptoms. Forty-seven patients (85.5%) exhibited
noisy breathing or snoring, and 18 (32.7%) had apneic
episodes. Laryngomalacia was diagnosed in five patients,
one of whom required supraglottoplasty at 4 months of
age. Concerns about airway obstruction frequently re-
sulted in adenoidectomy (n = 40; 72.7%; median age,
Table 1 Medical history, surgical history, and physical
examination findings
Medical and surgical history
(n = 55)
Physical examination
findings (n = 44)
Medical history
Acute or chronic otitis media 89.1% Joint restrictions 93.2%
Noisy breathing or snoring 85.5% Corneal clouding 81.8%
Hernia 63.6% Kyphosis 77.3%
Respiratory infections 54.5% Hypotonia 61.4%
Swallowing difficulty 45.5% Hepatomegaly 61.4%
Apnea 32.7% Transmitted upper
respiratory sounds
56.8%
Reflux 30.9% Nasal congestion 52.3%
Latching or sucking difficulty 21.8% Protuberant or distended
abdomen
45.5%
Diarrhea 18.2% Nasal drainage 40.9%
Reactive airway disease 16.4% Muscle weakness 29.5%
Constipation 12.7% Gingival hypertrophy 22.7%
Laryngomalacia 9.1% Murmur 22.7%
Surgical history Abnormal palate 20.5%
Adenoidectomy 72.7% Sacral dimple 18.2%
Tonsillectomy 61.8% Mongolian spots 15.9%
Tympanostomy tubes 78.2% Hirsutism 13.6%
Ventriculoperitoneal shunt 25.5% Strabismus 9.1%
Information about medical and surgical history was available for all 55
patients. Physical examination findings were available for the subset of
patients (n = 44) who were evaluated at our center prior to transplantation
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12.3 months) and/or tonsillectomy (n = 34; 61.8%; me-
dian age, 14.5 months). Nine patients (16.4%) also re-
quired treatment with nebulizers to address signs of
comorbid reactive airway disease.
Prior to transplantation 30 patients (54.5%) developed
respiratory infections, including pneumonia (n = 8;
14.5%). Many patients experienced persistent upper re-
spiratory symptoms even after the cessation of active
Fig. 2 Growth charts for height, weight, and head circumference by gender. Gray lines show the population percentiles 3%, 5%, 10%, 25%, 75%, 90%,
95%, and 97%. The blue line represents the 50th percentile. Each patient is represented by either a dot (single evaluation) or line (longitudinal data).
a Height-boys, b height-girls, c weight-boys, d weight-girls, e head circumference-boys and f head circumference-girls
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infections. On examination, nasal congestion (n = 23;
52.3%), drainage (n = 18; 40.9%), and transmitted upper
respiratory sounds (n = 25; 56.8%) were frequently
noted (Table 1).
Cardiovascular
Of the 42 patients with available echocardiogram and/or
electrocardiogram results, abnormalities were detected
in 35 (83.3%). Twenty-six patients (61.9%) had valve ab-
normalities, diagnosed at a median age of 13.0 months.
Valve insufficiency was present in 21 patients (50.0%).
The mitral valve was most commonly affected (n = 19),
followed by the tricuspid (n = 7) and aortic (n = 3) valves.
Fifteen patients (35.7%) had thickened or dysplastic
valves. Ten patients (23.8%) had ventricular hypertrophy.
Other findings included patent foramen ovale or atrial
septal defects (n = 9), ventricular dilation (n = 4), pa-
tent ductus arteriosus (n = 4), supraventricular tachy-
cardia (n = 4), atrial dilation (n = 2), pericardial
effusion (n = 2), and ventricular septal defects (n = 1).
At the time of evaluation 10 of 44 patients (22.7%)
had audible murmurs. The median age at the initial
detection of any cardiac abnormality was 9.5 months.
Other somatic manifestations
More than three-fourths of patients with available data
were found to have kyphosis on examination (n = 34;
77.3%; Table 1), which was identified at a median age of
8.6 months. Hepatomegaly, which was present in 27 pa-
tients (61.4%), was detected slightly later, at a median of
9.8 months. Twenty patients (45.5%) were noted to have
a protuberant or distended abdomen. Most patients (n =
35; 63.6%) also developed hernias. Inguinal hernias were
typically detected soon after birth, at a median of
1.5 months (n = 20; 36.4%), whereas umbilical hernias
did not appear until a median of 11.8 months (n = 26;
47.3%). Other findings included sacral dimples (n = 8),
Mongolian spots (n = 7), hirsutism (n = 6), hemangiomas
(n = 3), and café au lait spots (n = 1).
Neuromuscular manifestations
Most patients presented with neuromuscular abnormal-
ities. On examination, 27 (61.4%) were found to have
hypotonia, which was initially detected at a median age
of 10.1 months. Weakness of the trunk and/or extrem-
ities was noted in 29.5% (n = 13). The vast majority of
patients (n = 41; 93.2%) had restrictions in one or more
joints, most commonly in the shoulders. Joint restric-
tions were initially noted at a median of 10.3 months.
Upper extremity deep tendon reflexes, assessed in 39
patients, were diminished (1+) in 11 (28.2%), normal (2+)
in 27 (69.2%), and brisk (3+) in 1 (2.6%). Lower extremity
deep tendon reflexes, assessed in 41 patients, were
diminished in 7 (17.1%), normal in 27 (65.9%), and brisk
in 6 (14.6%). One patient had clonus in the lower
extremities.
Head growth and neuroimaging findings
At the time of evaluation, head circumference was above
the 50th percentile for most children and above the 95th
for many (Fig. 2). Concerns about enlarged head size
emerged at a median of 9.0 months. Fourteen children
(25.5%) required placement of a ventriculoperitoneal
shunt for hydrocephalus at a median of 10.7 months.
Pre-transplant brain MRI scans were available for 37
patients. The most frequent findings were white matter
abnormalities (n = 21; 56.8%), dilated Virchow-Robin
perivascular spaces (n = 22, 59.5%), volume loss (n = 17,
45.9%), dilated ventricles (n = 15, 40.5%), pituitary sella
abnormalities (n = 5, 13.5%), and enlarged extra-axial
cerebrospinal fluid spaces (n = 6, 16.2%). White matter
changes were noted as early as 6.8 months of age.
Neurodevelopmental functioning
The results of developmental testing are shown in Fig. 3.
Developmental age was plotted against chronological
age for each patient evaluated.
Cognition
Cognitive function was preserved in most children eval-
uated during the first year of life. Within this age group,
only three were outside the normal range in measures of
cognition. However, as a group these patients showed
lower cognitive functioning than normally developing
children. Cognitive development in children with Hurler
syndrome started to deviate from typical development
(gray lines) at approximately 9 months of age (Fig. 3a).
Adaptive behavior
Adaptive behavior was normal in most children evalu-
ated during the first year of life (Fig. 3b). However, as a
group they tested below the normal 50th percentile, and
this area of development become more abnormal over
time. Adaptive behavior scores tended to be superior to
cognitive and gross motor scores.
Motor
Gross motor function was the weakest area of develop-
ment in this cohort. Deficits generally became apparent
during the first year of life (Fig. 3c). In addition, many
patients failed to acquire early gross motor milestones
on time [18]. According to parent reports, 46.5% (20/43)
of the children did not sit independently until at least
8 months of age, 30.0% (6/20) did not crawl until at least
12 months of age, and 40.0% (8/20) did not walk inde-
pendently until at least 16 months of age.
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Fine motor skills were superior to gross motor skills in
most children (Fig. 3d). Within the first year of life there
was no obvious difference between the group mean and
typical development. However, starting at 12 months of
age the group mean (red line) began to plateau, becom-
ing more abnormal after 24 months.
Fig. 3 Developmental charts. The figures plot individual age-equivalent scores (y-axis) against the actual age of the patient (x-axis) for each of
the developmental domains. The red line represents the estimated group mean. a Cognitive development, b adaptive behavior, c gross motor,
d fine motor, e receptive language and f expressive language
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Language
Delays in both receptive and expressive language often
appeared during the first year of life (Fig. 3e & f). Seven
(33%) of the 21 children evaluated between 6 and
12 months of age showed below normal language scores
in receptive and expressive language.
Discussion
Information about the natural history of Hurler syn-
drome may help clinicians to manage infants diagnosed
with MPS I through newborn screening. With this study,
we characterized the early onset and progression of
neurological and somatic disease in patients with Hurler
syndrome. This represents, to our knowledge, the largest
and most comprehensive study of the natural progres-
sion of early symptoms of Hurler syndrome based on
systematic physical and neurodevelopmental evaluations
performed at a single center.
The patients in this cohort were diagnosed with MPS I
at a median age of nine months. Our group has previ-
ously demonstrated that transplantation of patients with
Hurler syndrome during the first nine months of life is
associated with normal cognitive development, while
those that are transplanted later show long-term deficits
[6]. In light of our finding that 98% of these patients
showed signs of disease during the first six months of
life, this represents an unacceptable delay in diagnosis.
Although the retrospective nature of this study pre-
cluded the determination of causal relationships, the
delay in treatment likely affected neurodevelopmental
outcomes in these patients. Recurrent otitis media, hear-
ing loss, and hypertrophy of the adenoids, tonsils, and
tongue may have contributed to expressive and receptive
language delays. Similarly, the presence of neuromuscu-
lar symptoms such as joint restrictions and hypotonia
likely hindered gross motor function, which was the
weakest area of development in these patients.
Although the addition of MPS I to the Recommended
Uniform Screening Panel constitutes an important step
towards minimizing diagnostic delays, the implementa-
tion of widespread newborn screening for this disorder
may take years, and many patients will likely continue to
be diagnosed with MPS I on the basis of clinical presen-
tation. Thus, increased awareness among primary care
providers about the initial symptoms of this disorder is
essential to facilitate early identification and treatment
of affected patients. More than a quarter of this cohort
failed the newborn hearing screen, and several had con-
genital anomalies such as cardiac defects, orthopedic de-
formities, and inguinal hernias. The vast majority of
patients also developed respiratory, otological, and/or
feeding difficulties during the first six months of life.
The nonspecific nature of these early symptoms likely
contributed to diagnostic delays; otitis media, which
occurred in nearly 90% of this cohort beginning a me-
dian of 6.5 months, has been found to affect more than
a third of all newborns during the first six months of life
[19]. Likewise, feeding difficulties, which were present in
more than 70% of this cohort, have been reported to
affect 25% of the typically developing population [20].
Pediatricians should be made aware that the occurrence
of these nonspecific symptoms in conjunction with other
characteristic signs of MPS I – such as kyphosis, corneal
clouding, and hepatomegaly, which had median onset
ages of 8–10 months in this cohort – warrants immedi-
ate evaluation for a lysosomal storage disorder.
The implementation of NBS for this disorder shows
promise to minimize diagnostic delays. Nonetheless,
the clinical management of screen-positive infants will
likely pose a number of challenges. The high prevalence
of early symptoms in this cohort suggests that infants
diagnosed with MPS I through NBS should be moni-
tored closely for signs and symptoms of disease onset,
since early hematopoietic stem cell transplantation im-
proves neurodevelopmental outcomes [6]. Given the
high incidence of feeding difficulties, upper respiratory
symptoms and hearing problems in this cohort, we rec-
ommend that when all of these are identified in the first
6 months of life in an infant who screens positive for
MPS I, the patient should be referred for further testing
to a specialized center to evaluate the presence of
neurological disease and make recommendations about
the need for transplantation. Although routine genetic
and biochemical tests are, individually, limited in their
ability to predict MPS I phenotype, approaches that in-
tegrate clinical and laboratory data may have greater
prognostic value. Kingma et al. (2013) proposed a
three-part algorithm that combined the results of gen-
etic testing, residual enzyme activity levels, and infor-
mation about two symptoms (upper airway obstruction
and inguinal hernias) during the first month of life to
predict whether an infant with MPS I will develop the
Hurler phenotype [12]. We propose adding to this algo-
rithm otitis media, sensorineural hearing loss and feed-
ing difficulties, since they commonly appeared soon
after birth and could potentially serve as early markers
of disease severity in patients with Hurler syndrome.
However, to validate these and any other potential
prognostic clinical markers, the progression and timing
of symptom onset will need to be compared between
patients with Hurler syndrome and those with attenu-
ated forms of MPS I. Unfortunately, the few studies
that have described the natural history of attenuated
MPS I phenotypes did not focus on disease manifesta-
tions during the first year of life [1, 21, 22] Thus, fur-
ther research is needed in this area.
As a retrospective review of clinical data, this study is
subject to a number of limitations. Complete medical
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records were not available for all patients. Moreover, infor-
mation about several symptoms such as feeding difficulties,
ear infections, and noisy breathing was obtained in part
through parent interviews, which are subject to recall bias.
For a number of other disease manifestations, the timing of
onset was ascertained by reviewing available medical re-
cords. Since delays may occur between the emergence of a
symptom and its detection by a medical professional, these
symptoms may have appeared sooner than our estimates
suggest, further highlighting the need for early and vigilant
monitoring of all infants with MPS I. The implementation
of newborn screening for this disorder may enable pro-
spective studies of the timing of symptom onset in affected
infants, thus overcoming many of the limitations of the
present study. Despite the study’s limitations, the use of a
predetermined protocol for physical examinations and
developmental testing carried out by professionals experi-
enced in working with children with neurodegenerative
disorders represents a major strength of the present study.
Conclusion
This study characterized the early progression and tim-
ing of symptom onset in infants with Hurler syndrome.
Information about the clinical course of this disorder is
needed to aid in the management of affected patients
and to facilitate assessment of treatment effectiveness,
especially in the context of NBS. It is hoped that a better
understanding of the early progression of Hurler syn-
drome will result in improved outcomes for affected
children.
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